Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTP4A2/PRL-2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTP4A2 (PRL-2) Recombinant Protein (WT & Mutants) High purity (>95%), Endotoxin controlled. Sequence Verified. Available with GST or His tags for surface chemistry. |
View PTP4A2 Products |
| Gene Delivery | PTP4A2 Promise-ORF / Lentivirus Particles Full-length ORF for stable cell line construction and overexpression assays. |
View PTP4A2 Products |
| Benchmark Ab | Anti-PTP4A2 Recombinant Reference Antibody Sequence-derived monoclonal antibody for assay setup and positive control. |
View PTP4A2 Products |
| Validator | PTP4A2 siRNA Set Target-specific gene knockdown validation. |
View PTP4A2 Products |
| Related Target A | PTP4A3 (PRL-3) Highly homologous phosphatase (over 85% sequence identity); essential for selectivity and counter-screening. |
View PTP4A3 Products |
| Related Target B | CNNM4 Magnesium transporter that forms a functional complex with PRL-2; critical for disrupting protein-protein interactions (PPI). |
View CNNM4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against highly homologous PTP4A/PRL family members (PRL-1, PRL-3) | Sequence-verified recombinant panels of PTP4A1, PTP4A2, and PTP4A3 with >95% purity for robust counter-screening. |
| Assaying Protein-Protein Interactions (PTP4A2-CNNM4 complex) | Truncated and full-length native-state proteins designed specifically for SPR/BLI binding and displacement assays. |
| Lack of Validated Controls | Recombinant benchmark antibodies and validated gene knockdown (siRNA) tools provided to establish baseline parameters. |
| Active-site mimicry and oxidation artifacts in enzyme assays | Strictly endotoxin-controlled, high-purity proteins with defined theoretical molecular weight and verified sequence identity. |
Live PTP4A2/PRL-2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTP4A2/PRL-2 therapeutics is intensifying, with major players shifting focus from traditional catalytic site inhibitors to allosteric modulators and protein-protein interaction (PPI) disruptors. Historically considered "undruggable" due to the highly conserved and charged nature of the phosphatase active pocket, PTP4A2 is now a prime candidate for novel modalities. As first-generation orthosteric inhibitors face selectivity hurdles, the next wave of R&D is targeting the PTP4A2-CNNM macromolecular interface to regulate intracellular magnesium homeostasis and suppress oncogenic pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic Consortia, Biotech Startups | Solid Tumors, Triple-Negative Breast Cancer (TNBC) | High-throughput screening (HTS) assay development (Requires stable PTP4A2-CNNM4 recombinant proteins) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Hematological Malignancies, Acute Myeloid Leukemia (AML) | Ternary complex validation assays (Requires tag-optimized WT and mutant PTP4A2 proteins) |
| Allosteric Inhibitors | Pharma Discovery Units | Metastatic Cancer, Colorectal Cancer | Selectivity profiling (Requires complete PTP4A family ortholog panel) |